These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16469447)

  • 1. The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression.
    Lee Y; Duman RS; Marek GJ
    Neurosci Lett; 2006 May; 398(3):328-32. PubMed ID: 16469447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.
    Gewirtz JC; Chen AC; Terwilliger R; Duman RC; Marek GJ
    Pharmacol Biochem Behav; 2002 Sep; 73(2):317-26. PubMed ID: 12117585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740.
    Marek GJ; Wright RA; Schoepp DD
    Neurosci Lett; 2006 Aug; 403(3):256-60. PubMed ID: 16759803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex.
    Swanson CJ; Perry KW; Schoepp DD
    J Neurochem; 2004 Jan; 88(1):194-202. PubMed ID: 14675163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
    J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine2A receptor activation.
    Zhang C; Marek GJ
    J Pharmacol Exp Ther; 2007 Jan; 320(1):437-47. PubMed ID: 17021259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
    Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
    Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex.
    Zhai Y; George CA; Zhai J; Nisenbaum ES; Johnson MP; Nisenbaum LK
    Neuropsychopharmacology; 2003 Jan; 28(1):45-52. PubMed ID: 12496939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.
    Monn JA; Prieto L; Taboada L; Pedregal C; Hao J; Reinhard MR; Henry SS; Goldsmith PJ; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Xiang C; Catlow JT; Swanson S; Sanger H; Broad LM; Johnson MP; Knopp KL; Simmons RM; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Feb; 58(4):1776-94. PubMed ID: 25602126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.
    Monn JA; Prieto L; Taboada L; Hao J; Reinhard MR; Henry SS; Beadle CD; Walton L; Man T; Rudyk H; Clark B; Tupper D; Baker SR; Lamas C; Montero C; Marcos A; Blanco J; Bures M; Clawson DK; Atwell S; Lu F; Wang J; Russell M; Heinz BA; Wang X; Carter JH; Getman BG; Catlow JT; Swanson S; Johnson BG; Shaw DB; McKinzie DL
    J Med Chem; 2015 Sep; 58(18):7526-48. PubMed ID: 26313429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.
    Di Liberto V; Bonomo A; Frinchi M; Belluardo N; Mudò G
    Neuroscience; 2010 Feb; 165(3):863-73. PubMed ID: 19909793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
    Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
    Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
    Felder CC; Schober DA; Tu Y; Quets A; Xiao H; Watt M; Siuda E; Nisenbaum E; Xiang C; Heinz B; Prieto L; McKinzie DL; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):190-197. PubMed ID: 28138041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.
    Monn JA; Valli MJ; Massey SM; Hao J; Reinhard MR; Bures MG; Heinz BA; Wang X; Carter JH; Getman BG; Stephenson GA; Herin M; Catlow JT; Swanson S; Johnson BG; McKinzie DL; Henry SS
    J Med Chem; 2013 Jun; 56(11):4442-55. PubMed ID: 23675965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
    Ferris P; Seward E; Dawson GR
    J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus.
    Linden AM; Baez M; Bergeron M; Schoepp DD
    Neuropharmacology; 2006 Aug; 51(2):213-28. PubMed ID: 16733060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.